Garidisan likely improved the quality of ulcer healing by reducing ICAM-1 expression and modifying the balance of CD3+CD4+ T cells/CD3+CD8+ T cells, Th1/Th2, and their secreted cytokines. This evidence concerns the gene CD8A and ulcer disease.